Am J Transplant, Volume 5, Suppl 3 Archives - Page 166 of 170 - ATC Abstracts

2015 American Transplant Congress
Vascularized Bone Marrow Plays a Critical Role in Inducing Tolerance of Osteomyocutaneous Allografts
C.-H. Lin,¹ M. Anggelia,¹ Y.-L. Wang,¹ H.-Y. Cheng,¹ W. Lee,² G. Brandacher.²
¹Center for Vascularized Composite Allotransplantation, Chang Gung Memorial Hospital, Taipei, Taiwan; ²Department of Plastic and Reconstructive Surgery, Johns Hopkins University School of Medicine, Baltimore, MD.
Background: Vascularized composite allograft (VCA) that includes medullary bone may provide proposed benefits ofvascularized bone marrow transplantation (VBMT), such as a continuous supply of donor…
2015 American Transplant Congress
1-Year Safety and Efficacy of Eculizumab in Adult aHUS Patients, With or Without a History of Renal Transplant
C. Legendre,¹ J. Kincaid,² C. Bedrosian,² C. Loirat.³
¹University Paris Descartes & Hôpital Necker, Paris, France; ²Alexion, Cheshire, CT; ³Assistance Publique–Hôpitaux Paris, Hôpital Robert-Debré, Paris, France.
Background: Atypical hemolytic-uremic syndrome (aHUS) is a life-threatening, chronic disease of complement-mediated TMA. In aHUS, renal transplantation is associated with post-transplant (TP) TMA and ∼50–70%…
2015 American Transplant Congress
Impact of Elevated BMI on Allograft Outcomes: A Competing Risks Regression Analysis
A. Naik, A. Sakhuja, M. Samaniego, P. Shrivastava, D. Cibrik.
Section of Nephrology, University of Michigan, Ann Arbor, MI.
INTRODUCTION: Extremes of BMI has been associated with an increased risk of death censored allograft failure. Traditionally the KM product limit estimate has been used…
2015 American Transplant Congress
The Impact of Acute Rejection on Liver Transplant Survival in the New Millennium
J. Levitsky,¹ S. Forney,² B. Gillespie,³ R. Merion,^2,3 A. Lok,³ G. Levy,⁴ L. Kulik,¹ M. Abecassis,¹ A. Shaked.⁵
¹Northwestern U, Chicago, IL; ²Arbor Research Collaborative for Health, Ann Arbor, MI; ³U Michigan, Ann Arbor, MI; ⁴U Toronto, Toronto, ON, Canada; ⁵U Pennsylvania, Philadelphia, PA.
Background: Based on pre-2000 data, acute rejection (AR) has long been considered clinically less significant in liver transplant (LT) vs. other organ recipients (Charlton et…
2015 American Transplant Congress
Post-Transplant Lymphoproliferative Disorders Following Alemtuzumab Induction in Kidney Transplantation
H. Sawhney, R. Charif, J. Galliford, A. Mclean, D. Taube.
Renal and Transplant Centre, Imperial College Healthcare NHS Trust, London, England, United Kingdom.
Post-Transplant Lymphoproliferative Disorder (PLTD) is a well-recognised serious complication in renal transplant recipients. Induction with lymphocyte depleting agents such as thymoglobulin has been associated with…
2015 American Transplant Congress
MDSC Derived from iPS Cells Regulate the CD8 T Cell Response In Vivo
D. Joyce,¹ M. Morita,² X.-K. Li,³ J. Fung,¹ S. Qian,^1,2 L. Lu.^1,2
¹General Surgery, Digestive Disease Institute; 2Immunology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH; ³Transplantation Immunology, National Research Institute for Child Health and Development, Tokyo, Japan.
Myeloid derived suppressor cells (MDSC) may represent a therapeutic tool for inducing tolerance in transplantation and autoimmune disorders. MDSC propagated from bone marrow (BM) can…
2015 American Transplant Congress
Deleterious Effects in Kidney Transplant Outcomes With Pre-Organ Procurement Iodine Contrast Exposure
F. Barrantes,¹ S. Stith.²
¹Renal Medicine Associates/Presbyterian Transplant Center, Albuquerque, NM; ²Department of Economics, University of New Mexico, Albuquerque, NM.
Background: Iodine contrast exposure is well known to cause acute kidney injury. When contrast exposure is added to hemodynamic ischemic injury its adverse effects on…
2015 American Transplant Congress
Th-17 Alloimune Responses in Renal Allograft Biopsies from Recipients of Kidney Transplants Using Extended Criteria Donors During Acute T-Cell Mediated Rejection
M. Matignon,^1,2 A. Aissat,³ F. Canoui-Poitrine,⁴ C. Grondin,² D. Desvaux,⁵ D. Saadoun,⁶ P. Lang,^1,2 J. Cohen,² P. Grimbert.^1,2
¹Nephrology Transplantation, APHP, Créteil, France; ²U955 Team 21, INSERM, Créteil, France; ³U955 Team 11, INSERM, Créteil, France; ⁴Public Health, APHP, Créteil, France; ⁵Anatomopathology, APHP, Créteil, France; ⁶Internal Medicine, APHP Pitié Salpêtrière, Paris, France.
Although renal transplantation using expanded criteria donors has become a common practice, immune responses related to immunosenescence in those kidney allografts have not been studied…
2015 American Transplant Congress
Biomarkers of Deceased Donors for the Prediction of Renal Allograft Outcomes
S. Kang,¹ H. Im,¹ J. Lee,¹ T. Koo,¹ S. Lee,² S. Park,³ S.-J. Kim,⁴ C. Ahn,¹ J. Yang.¹
¹Transplantation Center, Seoul National University Hospital, Seoul, Republic of Korea; ²Chonbuk National University Hospital, Jeonju, Republic of Korea; ³Inje University Busan Paik Hospital, Busan, Republic of Korea; ⁴Samsung Medical Center, Seoul, Republic of Korea.
Background: Better prognostic markers in deceased donors(DD) are needed for determining whether to accept suboptimal DD kidneys or predicting post-transplant outcomes. Recently, neutrophil gelatinase-associated lipocalin(NGAL),…
2015 American Transplant Congress
CD28-Directed Therapy Prolongs Survival in a Non-Human Primate Kidney Transplant Model
L. Higginbotham,¹ D. Mathews,¹ C. Breeden,¹ W. Wakwe,¹ C. Larsen,¹ S. Nadler,² A. Adams.¹
¹Emory Transplant Center, Emory University School of Medicine, Atlanta; ²Bristol-Myers Squibb, Princeton.
Introduction. Costimulation blockade using belatacept has the potential to improve long-term renal function and reduce cardiovascular risk by avoiding calcineurin inhibitors, yet higher rates and…